La Maddalena S.p.A.

Futó vizsgálatok

• Toboroz

  A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

  2025-523815-12-00· 3. fázis· Forrás

• Toboroz

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· 3. fázis· Forrás

• Toboroz

  Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation

  NCT03911193· 2. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· 3. fázis· Forrás

• Toboroz

  Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

  NCT05817903· 2. fázis· Forrás

• Fut, nem toboroz

  Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer

  NCT05578664· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

  NCT05526755· 2. fázis· Forrás

• Fut, nem toboroz

  Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

  NCT04722848· 3. fázis· Forrás

• Toboroz

  A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations

  NCT04811001· 2. fázis· Forrás

• Toboroz

  Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients

  2024-517200-10-00· 2. fázis· Forrás

• Toboroz

  Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

  NCT03968393· 4. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák2 toboroz
• Akut mieloid leukémia (AML)1 toboroz
• Áttétes emlőrák1 toboroz
• Gyermekkori daganatok1 toboroz
• Mielóma multiplex1 toboroz
• Pitvarfibrilláció1 toboroz
• Stroke (szélütés)1 toboroz
• Vesedaganat1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Toboroz

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Forrás

• Lezárult

  Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

  NCT05393024· Forrás

• Lezárult

  Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

  NCT05117242· 2. fázis· Forrás